Spleen stiffness test for advanced liver scarring
Part of Digestive system clinical trials.
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have MASLD (fatty liver disease not caused by alcohol).
- You have advanced liver scarring (fibrosis stage F3 or F4) or high liver stiffness on a non-invasive test (more than 15 kPa), or you have moderate liver stiffness (more than 8 kPa) and are scheduled for a liver biopsy.
- You do not have other causes of liver disease (like hepatitis, alcohol, or autoimmune conditions).
- You have not had liver cancer, a liver transplant, or serious liver-related complications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study checks if a simple blood test (LIVERFASt) can accurately measure liver fat and scarring compared to MRI. It may help patients avoid more invasive tests in the future.
This study uses a special ultrasound technique, called shear wave elastography, to measure liver stiffness during an endoscopic ultrasound (EUS) procedure. It aims to see how well this new method detects liver scarring (fibrosis) in people with fatty liver disease, compared to standard tests like FibroScan and liver biopsy.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
This study looks at whether measuring spleen stiffness and simple blood tests can predict if the liver will recover in people with decompensated cirrhosis. It may help doctors know which patients can improve with treatment.
Hear when a new MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.